Vetter to Implement Serializat?ion to Support Track-And-?Trace Efforts
Vetter has announced significant progress in its solution for state-of-the-art product packaging, designed to support the prevention of product counterfeiting. This innovative development is in response to expanded requirements by official regulatory agencies that require manufacturers to have clear identification of drugs on packaging. Vetter is successfully implementing its IT-solution and will offer its customers a range of serialization services as a basis for track-and-trace programs by the end of 2014.
Drug counterfeiting is a serious problem facing the industry and continues to grow unabated worldwide. To combat this issue, regulatory agencies have been seeking and implementing new methods to thwart the counterfeiters. Serialization of packaging has been considered one of the most effective solutions so far by many countries. The US, South Korea, and Brazil, as well as regions including the European Union, will be following suit in the coming years.
In this regard, Vetter, a contract development and manufacturing organization (CDMO) with extensive packaging experience, has designed an effective solution for its customers: a flexible serialization service, that forms the basis of track-and-trace programs. With this offer, the company is extending its existing services. These services include, for example, printing of Global Trade Item Numbers (GTIN) on packages, which has been requested by France and is expected to be requested by the US in 2015. Following the successful implementation of an initial IT solution, Vetter began implementing an engineering platform for serialization that is expected to be operational by the end of 2014. The service will support pharmaceutical and biotech companies in implementing their own track-and-trace programs for a secured and controlled supply chain.
“The Vetter serialization service will support growing customer and regulatory demands in the area of track-and-trace in the struggle against counterfeiting," says Thomas Otto, Managing Director. “This service, which we expect to have implemented by late 2014, is based upon a comprehensive concept study that we undertook. Our serialization service will enable that packages include unique identification necessary to support product security and supply chain efficiency."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance